<DOC>
	<DOC>NCT00927836</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.</brief_summary>
	<brief_title>AXIS 2: AX200 for the Treatment of Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Major diagnosis of acute ischemic stroke with an onset within 9 hours prior to start of study agent administration ischemic stroke in the MCA territory confirmed by MRI (diffusion) age ≥18 years and ≤85 years lesion size on DWI ≥15 ccm written informed consent Major prior to current stroke: inability to walk or to lead an independent life life expectancy less or equal 6 months stupor or coma lacunar infarct any evidence of ICH malignant hypertension presence of history of active malignancies platelet count &lt;100/nl at randomization leukocyte count &gt;20/nl at randomization congenital neutropenia pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>